PRAME-targeted TCR-modified NK cells
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for PRAME-targeted TCR-modified NK cells, covering 2025-12-23 to 2025-12-23. Get the full timeline:
Most recent: Clinical Trial Update: Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies [Phase 1, Phase 2]